Fosun Pharma replaces CFO! Is this more than just an HR adjustment—could it be a major upgrade in financial strategy?

Ask AI · How does Huang Zhi’s cross-border background empower Fosun Pharmaceutical’s global strategy?

Produced by | China Visit Network

Reviewed by | Li Xiaoyan

On April 2, Fosun Pharmaceutical released a personnel announcement: Chief Financial Officer Chen Zhanyu stepped down due to a work adjustment and was transferred to become the company’s Senior Vice President. On the same day, Huang Zhi took over as Senior Vice President and Chief Financial Officer, and also served concurrently as Co-President of the Innovative Drug Business Unit. This seemingly routine personnel reshuffle is not simply a change of positions; it is a key move by Fosun Pharmaceutical to adapt to industry changes and deepen its strategic layout. It marks a comprehensive upgrade of its financial system—from traditional accounting to full-scale strategic value creation.

This adjustment shows two distinct features: personnel retention and the reconfiguration of responsibilities and authority. After Chen Zhanyu resigned as CFO, he remained as an executive. The new leader Huang Zhi moved in quickly, achieving seamless continuity. Such an operation—“changing the people without changing the generals, changing the roles without changing the intention”—is not common among large pharmaceutical companies. It not only avoids a break in core management, but also conveys the company’s stability in corporate governance.

From the timing perspective, the adjustment took place after the company disclosed its 2025 annual report. At that point, the company’s financial close was steady, and performance data had already landed. In 2025, Fosun Pharmaceutical achieved operating revenue of 41.66B yuan, with overseas revenue reaching 12.98B yuan, accounting for more than 31%. Innovative drug revenue continued to expand. Choosing this moment to appoint a new leader reflects an active plan based on long-term strategy, not a passive reaction to problems—demonstrating the management’s precise control over development pace.

The background of the new CFO, Huang Zhi, is the biggest highlight of this adjustment. He has worked for multiple leading enterprises, including Novartis, BeiGene, and Ascentage Pharma. He has spent years focusing on multinational pharma financial control and global commercial finance. Unlike traditional financial executives, Huang Zhi brings three core advantages:

First, global financial operations capability. During his time at Novartis, he led the development of the global finance and control framework and is familiar with regulatory rules in the major markets of Europe and the U.S., as well as cross-border funds management and tax planning. At BeiGene, he served as CFO for Greater China and global commercial finance, deeply understanding the logic of multi-region coordination in multinational pharmaceutical companies—this aligns closely with Fosun Pharmaceutical’s strategy of moving from “selling products overseas” to “exporting the system.”

Second, insights into the full life cycle finance of innovative drugs. He has long served innovation-drug companies, familiar with the characteristics of high R&D investment, long cycles, and high risk. He can accurately grasp core links such as clinical-stage spending, commercial return calculations, and value assessment for BD projects. With the share of Fosun Pharmaceutical’s innovative drug revenue continuing to rise and R&D investment remaining among the industry’s leaders, Fosun needs a finance captain who understands both the business and innovation.

Third, deep integration of business and finance. This time, Huang Zhi concurrently serves as CFO and Co-President of the innovative drug business unit, breaking down departmental barriers between finance and business. This ensures that financial decisions are directly embedded into the entire process of innovative drug R&D, clinical development, and commercialization—realizing “money follows projects, and benefits are calculated precisely,” thereby steering resources toward high-value innovative pipelines.

The core of this CFO reshuffle is the strategic upgrade of Fosun Pharmaceutical’s financial system. Traditional CFOs focus on budgeting, accounting, and risk control. In the new era, financial leaders have become core participants in a company’s strategy.

For Fosun Pharmaceutical, the industry environment is undergoing profound change: R&D investment in innovative drugs continues to rise, the return cycle lengthens, and centralized procurement and market competition compress profitability. Globalization brings multiple challenges to cross-border funds, compliance, and risk control. This requires finance to no longer be merely post-event accounting, but full-process value management with forward-looking prediction, in-process control, and post-event review.

Huang Zhi’s arrival is precisely to address this key proposition: balancing innovation investment with cash flow, optimizing global resource allocation, and improving the precision of BD and investment decision-making. By deeply involving finance in the operations of the innovative drug business unit, every R&D investment, every overseas project, and every commercial cooperation can achieve more refined input-output measurement. This makes the innovation business—often seen as “burning cash”—more sustainable.

This adjustment clearly reflects Fosun Pharmaceutical’s two strategic directions: first, deepening the innovative drug strategy and building a refined R&D management system. At present, the company’s innovative drugs have become the core engine of performance. In the first three quarters of 2025, innovative drug revenue exceeded 6.7 billion yuan. Through an integrated approach to finance and business, strengthen the economic evaluation of R&D projects, eliminate low-efficiency pipelines, focus on advantageous areas, improve the efficiency of innovation transformation, and address the industry pain point of “high input and slow return.” Second, accelerating global expansion and building a world-class multinational pharma enterprise structure. In 2025, the overseas revenue share of the company surpassed 31%, and products have been approved in more than 40 countries worldwide. Huang Zhi’s multinational finance experience will help Fosun Pharmaceutical refine global financial control, optimize overseas tax structures, and improve the efficiency of cross-border funds operations—supporting the globalization strategy of “breakthrough in Europe and the U.S., and deep cultivation in emerging markets.”

Fosun Pharmaceutical’s adjustment also brings important lessons to the pharmaceutical industry. As innovation and globalization become mainstream trends, the CFO role is undergoing a disruptive transformation: you need to understand finance, but more importantly, you must understand the business; you need to understand China, but more importantly, you must understand the global environment; you need to understand compliance, but more importantly, you must understand value creation.

In the future, the core financial talent in the pharmaceutical industry must combine financial professional capability, an understanding of the innovative drug industry, a global operational perspective, and the ability to judge BD projects. The scarcity of such composite talent will also drive an upgrade of the industry’s talent structure, forcing companies to cultivate or recruit “finance + business + strategy” cross-disciplinary managers.

Of course, there are also some challenges that still need to be validated in this adjustment. The new leader Huang Zhi joined Fosun in February and took on a core role in April. More time is still needed to build familiarity with the group’s complex business system and to reach alignment with the existing management team. At the same time, the deep integration of finance and innovative drug business needs to balance control and innovation, avoiding excessive financial constraints that could dampen R&D enthusiasm. In addition, under global business expansion, realistic tests for the new team will also include cross-border financial compliance and the risk control of exchange rate fluctuations.

Overall, Fosun Pharmaceutical’s CFO reshuffle is a strategic upgrade rooted in the long term and driven by proactive change. By introducing composite financial talent with global and innovative drug backgrounds, it will push the finance function from the back office to the front stage—from accounting to strategy—injecting stronger momentum into both innovation and globalization engines. For the industry, this shift also confirms a trend: in the stage of high-quality development, competition among pharmaceutical companies is no longer limited to products and technology; it is a comprehensive contest of management systems, talent structure, and strategic execution capability.